Corbus Pharmaceuticals Holdings, Inc. Retained Earnings
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Retained Earnings of -$613.44 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$613.44M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$578.40M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$555.43M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$534.88M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$613.44M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$578.40M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$555.43M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$534.88M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$511.53M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | -$493.87M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | -$476.89M 10-K · filed 2026-03-09 | |
| 2024-09-30 | -$467.36M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$453.58M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | -$443.58M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | -$436.68M 10-K · filed 2025-03-11 | -$436.68M 10-K · filed 2024-03-12 |
| 2023-09-30 | -$428.66M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$418.61M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$409.83M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$392.08M 10-K · filed 2024-03-12 | |
| 2022-09-30 | -$381.20M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | -$372.42M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | -$359.17M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | -$349.73M 10-K · filed 2023-03-07 | |
| 2021-09-30 | -$339.47M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$337.30M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$320.16M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$304.09M 10-K · filed 2022-03-08 | |
| 2020-09-30 | -$295.48M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | -$260.59M 10-Q/A · filed 2020-08-31 | |
| 2020-03-31 | -$222.48M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$192.82M 10-K · filed 2021-03-15 | |
| 2019-09-30 | -$166.24M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | -$145.45M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$147.61M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$121.37M 10-K · filed 2020-03-16 | |
| 2018-09-30 | -$104.06M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$89.46M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | -$77.39M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | -$65.70M 10-K · filed 2019-03-12 | |
| 2017-09-30 | -$55.00M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | -$48.04M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$40.74M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | -$33.28M 10-K · filed 2018-03-12 | |
| 2016-09-30 | -$25.71M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | -$20.36M 10-Q · filed 2016-08-12 | |
| 2016-03-31 | -$16.17M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | -$13.28M 10-K · filed 2017-03-08 | |
| 2015-09-30 | -$10.78M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | -$8.53M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | -$5.96M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | -$4.43M 10-K · filed 2016-03-28 | |
| 2014-09-30 | -$3.17M 10-Q · filed 2014-11-13 | |
| 2013-12-31 | -$1.89M 10-K · filed 2015-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |